Compare Ascendis Pharma A/S (ASND) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Avantis US Small Cap Value ETF — how do they compare? Ascendis Pharma A/S trades at $257.5 (market cap $16.67B), while Avantis US Small Cap Value ETF trades at $127.78. The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ASND | AVUV | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $128.74 |
52-Week Low | $189.74 | $93.93 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
AVUV, a U.S. small-cap value ETF, trades at $127.51, up 0.4% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong 2026 performance, outpacing the Russell 2000, and positioning it as a diversification tool for tech-heavy portfolios. The fund benefits from a shift toward value stocks and potential rate cut tailwinds.
The outlook for AVUV is positive, driven by small-cap value momentum and investor rotation away from large-cap concentration. Key risks include sensitivity to interest rates, regional bank exposure, and higher small-cap volatility. Analyst sentiment is optimistic, with media coverage emphasizing its role in balanced long-term strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
